ClinicalTrials.gg
RecruitingNCT07043400Updated Oct 14, 2026

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of Subcutaneous Tislelizumab and Intravenous Tislelizumab in Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by BeOne Medicines. Recruiting at 95 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 14, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

02

Conditions studied

  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, locally advanced unresectable or gastric/ gastroesophageal junction (GEJ) adenocarcinoma.
  • No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
  • At least 1 measurable or nonmeasurable lesion per v1.1 as determined by investigator assessment.
  • Must be able to provide tumor tissues for biomarker assessment.
  • (ECOG) Performance Status score ≤ 1.
  • Adequate organ function.
  • Women of must be willing to use a highly effective method of for the duration of the study and ≥ 120 days after the last dose of tislelizumab.
  • Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of tislelizumab.

Exclusion criteria

Exclusion Criteria:

  • Squamous cell or undifferentiated or other histological type gastric cancer (GC)
  • Active or uncontrolled . Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for treatment for ≥ 4 weeks before randomization.
  • Diagnosis with gastric or GEJ adenocarcinoma with positive human epidermal growth factor receptor 2 ().
  • Active diseases or history of autoimmune diseases that may relapse.
  • Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (at least once a week) and/or diuretics within 7 days prior to randomization

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
351 participants (estimated)

Study arms

  • Experimental
    Arm A: Tislelizumab Subcutaneous + Chemotherapy

    Participants will receive tislelizumab 300 mg subcutaneous (SC) injection on Day 1 of each 21-day cycle, followed by chemotherapy decided on an individual patient basis.

    Drug: Subcutaneous Tislelizumab · Drug: Cisplatin · Drug: Leucovorin · Drug: 5-fluorouracil (5-FU) · Drug: Oxaliplatin · Drug: Capecitabine

  • Active comparator
    Arm B: Tislelizumab Intravenous Infusion + Chemotherapy

    Participants will receive tislelizumab 200 mg intravenous infusion (IV) on Day 1 of each 21-day cycle, followed by chemotherapy decided on an individual patient basis.

    Drug: Intravenous Tislelizumab · Drug: Cisplatin · Drug: Leucovorin · Drug: 5-fluorouracil (5-FU) · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Model-Predicted Steady State Trough Concentration (Ctrough) of Tislelizumab

    Time frame: 85 Days

  2. Model-Predicted Area under the Concentration-time Curve from Time Zero to 21 Days (AUC0-21d) after the First Dose of Tislelizumab

    Time frame: 21 Days

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to 2 years

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization date until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.1

    Time frame: Up to 2 years

  3. Duration of Response (DOR)

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first as assessed by the investigator using RECIST v1.1

    Time frame: Up to 2 years

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as assessed by the investigator using RECIST v1.1

    Time frame: Up to 2 years

  5. Overall Survival (OS)

    OS is defined as the time from first study drug administration to the date of death due to any cause

    Time frame: Up to 2 years

  6. Number of Participants With Adverse Events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, vital signs, physical examination findings, and electrocardiogram results.

    Time frame: Up to 2 years

  7. Model-predicted Serum Ctrough at Cycle 1

    Time frame: 21 Days

  8. Observed Serum Ctrough at Cycle 1

    Time frame: 21 Days

  9. Observed Area Under the Concentration-time Curve at Steady-state (AUC) at Cycle 1

    Time frame: 21 Days

  10. Model-predicted Area Under the Concentration-time Curve at Steady-state (AUCss)

    Time frame: 85 Days

  11. Percentage of Participants with Antidrug Antibodies (ADAs) to Tislelizumab after SC or IV Administration

    Time frame: Up to 2 years

07

Study locations

88 of 95 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Oct 30, 2027
CompletionEst.
Apr 22, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Tochigi Cancer Center is now Active, not recruiting
Show site
  • Baylor Scott and White Medical Center Temple · Temple, United States
Show 1 removed
  • Scott and White Memorial Hospital · Temple, United States
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added, 1 site removed. Tochigi Cancer Center is now Active, not recruiting
    Show site
    • Baylor Scott and White Medical Center Temple · Temple, United States
    Show 1 removed
    • Scott and White Memorial Hospital · Temple, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07043400
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Aug 27, 2025
Primary completion
Oct 30, 2027 (estimated)
Completion
Apr 22, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

BeOne Medicines
Contact
clinicaltrials@beonemed.com
1-877-828-5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion